Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35302596/
doi: 10.1158/1078-0432.CCR-21-3581. Online ahead of print. 1 Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, mi, United States. 2 Karmanos Cancer Institute, Detroit, United States. 3 Caris Life Sciences (United States), Phoenix, AZ, United States. 4 Fox Chase Cancer Center, Philadelphia, PA, United States.
Conclusions: KRAS-WT PDAC represents 10.7% of PDAC and is enriched with targetable alterations, including immuno-oncologic markers. Identification of KRAS-WT patients in clinical practice may expand therapeutic options in a clinically meaningful manner.